Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Jump to: 2015
Number of items: 3.

2015

Munir, T., O'Brien, S., Jones, J. A., Coutre, S. E., Mato, A. R., Hillmen, P., Tam, C., Osterborg, A., Siddiqi, T., Thirman, M. J., Furman, R. R., Ilhan, O., Keating, M., Call, T. G., Brown, J. R., Stevens-Brogan, M., Li, Y., Clow, F., James, D., Chu, A., Hallek, M. and Stilgenbauer, S. (2015). Results from the phase 2 RESONATE (TM)-17 Trial: Efficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic leukaemia with 17p deletion. Br. J. Haematol., 169. S. 71 - 72. HOBOKEN: WILEY. ISSN 1365-2141

Munir, T., O'Brien, S., Jones, J. A., Coutre, S. E., Mato, A. R., Hillmen, P., Tam, C., Osterborg, A., Siddiqi, T., Thirman, M. J., Furman, R. R., Ilhan, O., Keating, M., Call, T. G., Brown, J. R., Stevens-Brogan, M., Li, Y., Clow, F., James, D., Chu, A., Hallek, M. and Stilgenbauer, S. (2015). Results from the phase 2 RESONATE (TM)-17 Trial: Efficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic leukaemia with 17p deletion. Br. J. Haematol., 169. S. 71 - 72. HOBOKEN: WILEY. ISSN 1365-2141

Stilgenbauer, S., Jones, J. A., Coutre, S. E., Mato, A. R., Hillmen, P., Tam, C., Osterborg, A., Siddiqi, T., Thirman, M. J., Furman, R. R., Ilhan, O., Keating, M., Call, T. G., Brown, J. R., Stevens-Brogan, M., Li, Y., Clow, F., James, D. F., Chu, A. D., Hallek, M. and O'Brien, S. (2015). Results from the phase 2 RESONATE (TM)-17 trial: Efficacy and safety of Ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma with Del17p. Oncol. Res. Treat., 38. S. 92 - 93. BASEL: KARGER. ISSN 2296-5262

This list was generated on Sun Nov 28 03:17:58 2021 CET.